Search results
Study: Older Adults With Aggressive Blood Cancer A | Newswise
Newswise· 6 days agoStandard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Alaska Superstation· 2 days agoSeniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted...
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to...
Nature· 2 days agoIn contrast to B-cell precursor acute lymphoblastic leukemia (ALL), molecular subgroups are less well defined in T-lineage ALL. Comprehensive studies on ...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 3 days agoAML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated ...
Earnings call: Aptose Biosciences targets AML treatment with tuspetinib By Investing.com
Investing.com· 24 hours agoAptose Biosciences (NASDAQ:APTO) has focused its efforts on developing tuspetinib as part of a novel...
Opinion | Ending Oncology's Toxic Relationship With High Chemotherapy Doses
MedPage Today· 6 days agoMany years ago, my patient, a woman in her fifties with chronic myeloid leukemia (CML), got her...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoHONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306
Earnings call: Bio-Path Holdings reports promising Q1 2024 results By Investing.com
Investing.com· 23 hours agoBio-Path Holdings (NASDAQ: NASDAQ:BPTH), a biotechnology company focused on developing therapeutic...
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 7 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma ...
Aptose Reports Results for the First Quarter 2024
Digital Journal· 2 days agoTUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed ...
